Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137303 · ClinicalTrials.gov registry record · Phase 3
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
A Phase 3 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT03137303 is a Phase 3 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 402 participants.
The verdict
NCT03137303, a Phase 3 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.
Interventions
- DRUG Albuterol
- DEVICE Spirometry at initial visit
- DEVICE Spirometry at 12-month follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137303
The ClinicalTrials.gov registry entry for NCT03137303 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Albuterol is the first listed.
NCT03137303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137303 about?
NCT03137303 is a clinical study titled "Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)". The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.
What is the current status of trial NCT03137303?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2017-07-01. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03137303?
The interventions under investigation include: Albuterol (DRUG), Spirometry at initial visit (DEVICE), Spirometry at 12-month follow-up (DEVICE).
Who is sponsoring clinical trial NCT03137303?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.